Company research / IMUX

Immunic, Inc. (IMUX)

SEC name IMMUNIC, INC. · CIK 0001280776 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-18

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-10, first reflected in a filing dated 2026-05-13. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
R&D Expense$90.64M$81.98M$80.05M$83.22M$71.25M$61.12M$38.64M$22.51M$9.60M$39.34M$30.05M
Operating Income-$117.88M-$103.23M-$98.05M-$99.22M-$119.49M-$91.67M-$48.97M-$37.03M-$12.00M-$52.66M-$41.27M
Depreciation & Amortization$149.0K$168.0K$134.0K$111.0K$77.0K$85.0K$39.0K$50.0K$15.0K$998.0K$1.81M
EBITDA-$117.73M-$103.06M-$97.92M-$99.11M-$119.41M-$91.58M-$48.93M-$36.98M-$11.98M-$51.66M-$39.46M
Net Income-$111.57M-$97.17M-$100.51M-$93.61M-$120.41M-$92.94M-$44.02M-$34.93M-$11.54M-$52.08M-$40.97M
EPS (Diluted)n/a-$0.62-$1.00-$2.11-$3.78-$3.93-$2.81n/an/an/an/a
Total Assets$159.17M$24.05M$40.87M$54.30M$127.75M$139.10M$167.86M$65.95M$13.37M$60.38M$64.03M
Total Liabilities$31.59M$30.73M$22.44M$25.37M$14.07M$11.98M$9.08M$7.59M$1.92Mn/an/a
Shareholders' Equity$127.58M-$6.67M$18.43M$28.93M$113.68M$127.11M$158.78M$58.36M-$25.74M$50.04M$58.45M
Cash & Equivalents$155.10M$15.48M$35.67M$46.67M$106.75M$86.86M$127.45M$29.37M$13.07M$56.90M$59.99M
Operating Cash Flow-$87.72M-$85.81M-$84.77M-$70.83M-$65.14M-$83.23M-$46.12M-$28.55M-$9.74M-$40.40M-$35.77M
Capital Expenditures$329.0K$161.0K$264.0K$334.0K$112.0K$67.0K$146.0K$55.0K$32.0K$685.0K$556.0K
Free Cash Flow-$88.05M-$85.97M-$85.03M-$71.16M-$65.26M-$83.30M-$46.27M-$28.60M-$9.77M-$41.08M-$36.33M
Shares Outstanding13.64M90.15M90.15M45.18M39.31M26.34M21.17M10.74M847.0K42.37M32.14M
Dividends Per Sharen/a$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00n/an/a
Weighted Average Diluted Sharesn/a155.69M100.17M44.32M31.82M23.65M15.66Mn/an/an/an/a
EPS (Basic)n/a-$0.62-$1.00-$2.11-$3.78-$3.93-$2.81n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView